南非未来HIV流行趋势及减少普通人群HIV检测的长期后果预测:一项数学建模研究
该建模研究使用Thembisa 4.5模型预测南非至2100年的HIV流行,假设2022年疫情与项目条件持续。若维持2022年普通人群HIV检测,HIV年发病率将从2025年4.95/1000降至2100年0.14/1000,2055年达到虚拟消除阈值。2025年减少普通人群检测25%、50%、75%分别延迟达阈5、13、35年,完全停止则2100年前无法达标。
要点
- 维持2022年检测强度,HIV发病率从2025年4.95/1000降至2100年0.14/1000,2055年达虚拟消除阈值。
- 2025年减少普通人群检测25%、50%、75%分别延迟达阈5、13、35年,完全停止则2100年前不达标。
核心结论
- 建模提示减少普通人群HIV检测不会导致HIV感染复燃,但会延迟发病率下降目标的实现,并长期增加HIV感染、AIDS相关死亡和成本(因ART需求增加)。
研究设计与样本
- 使用Thembisa 4.5模型(南非HIV传播确定性房室模型)将南非HIV流行预测至2100年,假设2022年流行病学条件和HIV项目实施持续。
- 评估2025年减少普通人群HIV检测服务(同时保持产前、症状性和风险导向检测及其他HIV预防服务在2022年水平)对15–49岁人群HIV发病率和患病率、达到虚拟消除阈值(每1000名15–49岁人群每年新发感染少于1例)的年份及相关成本的影响。
主要发现
- 若维持2022年普通人群HIV检测服务和HIV风险环境,HIV发病率从2025年4.95(95%CI 4.40–5.34)/1000人口稳步下降至2100年0.14(95%CI 0.05–0.31)/1000,并在2055年(95%CI 2051–2060)达到虚拟消除阈值(每1000人口每年新发感染少于1例)。
- 2025年普通人群HIV检测服务减少25%、50%、75%分别使达到虚拟消除阈值的时间延迟5年、13年、35年,完全停止普通人群检测则2100年前无法达到阈值。
- 将普通人群HIV检测服务减少延迟5–25年可减轻部分上述影响。
- HIV检测仅占基线项目总成本的5%;适度减少检测可降低短期年度总成本,但25年后年度成本增加。
临床怎么用
- HIV项目需要在短期潜在资源节省与长期疫情控制目标之间取得平衡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: After successful intensive interventions to rapidly increase HIV awareness, coverage of antiretroviral therapy (ART), and viral suppression, HIV programmes in eastern and southern Africa are considering scaling back of some interventions, such as widespread general population HIV testing. We aimed to model whether scaling back of general population HIV testing in South Africa could result in a resurgence of the HIV epidemic or substantial slowing of declines in HIV incidence, resulting in increased long-term ART. METHODS: In this modelling study, we used the Thembisa 4.5 model (a deterministic compartmental model of HIV transmission in South Africa) to project the South African HIV epidemic to 2100 assuming the continuation of 2022 epidemiological conditions and HIV programme implementation. We assessed how implementing reductions in general population HIV testing services in 2025 (while maintaining antenatal, symptom-based, and risk-based testing modalities and other HIV prevention services at 2022 levels) would affect HIV incidence and prevalence among people aged 15-49 years, the year in which incidence would reach one per 1000 people aged 15-49 years (the threshold for virtual elimination of HIV), and associated costs, as well as numbers of additional new HIV infections and AIDS-related deaths. We also modelled the effects of delaying reductions in general population testing services by 5-year increments. Additionally, we modelled the potential effects of reductions in general population testing services in combination with increases or decreases in ART interruption rates (ie, the annual rate at which people who are on ART discontinue ART) and condom usage in 2025-35. FINDINGS: If general population HIV testing services and the HIV risk environment of 2022 were maintained, we projected that HIV incidence would steadily decline from 4·95 (95% CI 4·40-5·34) per 1000 population in 2025 to 0·14 (0·05-0·31) per 1000 in 2100, and that the so-called virtual elimination threshold of less than one new infection per 1000 population per year would be reached in 2055 (95% CI 2051-2060). Scaling back of general population HIV testing services by 25%, 50%, or 75% in 2025 delayed time to reaching the virtual elimination threshold by 5, 13, or 35 years, respectively, whereas complete cessation of general population testing would result in the threshold not being attained by 2100. Although the incidence of HIV continued to fall when general HIV testing services were reduced, our modelling suggested that, with reductions of between 25% and 100%, between 396 000 (95% CI 299 000-474 000) and 2·50 million (1·97 million-2·98 million) additional HIV infections and between 115 000 (94 000-135 000) and 795 000 (670 000-926 000) additional AIDS-related deaths would occur between 2025 and 2075, depending on the extent of reduction in testing. Delaying reductions in general population HIV testing services for 5-25 years mitigated some of these effects. HIV testing accounted for only 5% of total programmatic costs at baseline; reducing testing moderately reduced short-term total annual costs, but increased annual costs after 25 years. Increases in ART interruption and reductions in condom usage were projected to slow the decline in incidence and increase the coverage of general HIV testing services required to control transmission but did not cause rapid resurgence in HIV infections. INTERPRETATION: Our modelling suggests that scaling back of general population HIV testing would not result in a resurgence of HIV infections, but would delay attainment of incidence-reduction targets and result in long-term increases in HIV infections, AIDS-related deaths, and costs (via increased need for ART provision). HIV programmes need to balance short-term potential resource savings with long-term epidemic control objectives. FUNDING: Bill & Melinda Gates Foundation.
引用
- Rautenbach SP, Whittles LK, Meyer-Rath G, et al. Future HIV epidemic trajectories in South Africa and projected long-term consequences of reductions in general population HIV testing: a mathematical modelling study. Lancet Public Health. 2024. PMID: 38553141. doi:10.1016/S2468-2667(24)00020-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。